Drugs / Ad-RTS-hIL-12
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03679754 | Sep 2018 → Apr 2019 | glioblastoma | Alaunos Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03636477 | Jun 2018 → Oct 2020 | glioblastoma | Alaunos Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02026271 | Jun 2015 → Aug 2019 | anaplastic oligoastrocytoma, glioblastoma | Alaunos Therapeutics | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03330197 | Sep 2017 → Sep 2021 | diffuse intrinsic pontine glioma | Alaunos Therapeutics | Terminated | No outcome recorded |
| Phase 1/2 | NCT02423902 | Jul 2015 → Jul 2016 | breast cancer | Alaunos Therapeutics | Terminated | No outcome recorded |
| Phase 1/2 | NCT01397708 | Aug 2011 → Sep 2014 | melanoma | Alaunos Therapeutics | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04006119 | Aug 2019 → Aug 2021 | glioblastoma | Alaunos Therapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT01703754 | Apr 2013 → Aug 2014 | breast carcinoma | Alaunos Therapeutics | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad-RTS-hIL-12 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03330197 ↗ |
| Known as | INXN-2001 | “evaluating the safety and efficacy of INXN-1001 (veledimex) and INXN-2001 (Ad-RTS-hIL-12) alone and in combination with palifosfamide.” NCT01703754 ↗ |
| Route | Other | “adenoviral vector injection of cancer lesions” NCT01703754 ↗ |